Dendritic cells modified with 6Ckine/IFNγ fusion gene induce specific cytotoxic T lymphocytes in vitro

Cancer Immunology, Immunotherapy

Volumn 56, Issue 11, 2007, Pages 1831-1843

  Xue, Gang ^c   Liu, Ran Yi ^a   Li, Yan ^a   Cheng, Ying ^c   Liang, Zhi Hui ^a   Wu, Jiang Xue ^a   Zeng, Mu Sheng ^a   Tian, Fu Zhou ^c   Huang, Wenlin ^a,b  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b INSTITUTE OF MICROBIOLOGY   (China)

^c CHENGDU MILITARY GENERAL HOSPITAL   (China)

Author keywords

Chemokines; Cytokines; Dendritic cells; Gene therapy; Tumor immunology

Indexed keywords

ADENOVIRUS VECTOR; CD83 ANTIGEN; CHEMOKINE RECEPTOR CCR7; GAMMA INTERFERON; HYBRID PROTEIN; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 2; RANTES; SECONDARY LYMPHOID TISSUE CHEMOKINE; TRANSCRIPTION FACTOR T BET;

ARTICLE; CANCER CELL CULTURE; CELL MATURATION; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DENDRITIC CELL; DOWN REGULATION; FUSION GENE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VITRO STUDY; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE PROLIFERATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION; TH1 CELL; TUMOR IMMUNOLOGY; UPREGULATION; VIRAL GENE DELIVERY SYSTEM;

ADENOVIRIDAE; ANGIOGENESIS INHIBITORS; CELL LINE, TUMOR; CHEMOKINES, CC; DENDRITIC CELLS; GENE THERAPY; GENETIC VECTORS; HUMANS; INTERFERON TYPE II; LYMPHOCYTE ACTIVATION; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; TRANSFECTION;

EID: 34548161595     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-007-0327-y     Document Type: Article

References (51)

1. Lanzavecchia A, Sallusto F (2001) Regulation of T cell immunity by dendritic cells. Cell 106:263-266
2. Mihich E (2003) Cellular immunity for cancer chemoimmunotherapy-an overview. Cancer Immunol Immunother 52:661-662
3. Bell D, Young JW, Banchereau J (1999) Dendritic cells. Adv Immunol 72:255-324
4. Evel-Kabler K, Chen SY (2006) Dendritic cell-based tumor vaccines and antigen presentation attenuators. Mol Ther 13:850-858
5. Yang SC, Batra RK, Hillinger S et al (2006) Intrapulmonary administration of CCL21 gene-modified dendritic cells reduces tumor burden in spontaneous murine bronchoalveolar cell carcinoma. Cancer Res 66:3205-3213
6. Lundqvist A, Choudhury A, Nagata T et al (2002) Recombinant adenovirus vector activates and protects human monocyte-derived dendritic cells from apoptosis. Hum Gene Ther 13:1541-1549
7. Miller G, Lahrs S, Pillarisetty VG et al (2002) Adenovirus infection enhances dendritic cell immunostimulatory properties and induces natural killer and T-cell-mediated tumor protection. Cancer Res 62:5260-5266
8. Kirk CJ, Hartigan-O'Connor D, Mule JJ (2001) The dynamics of the T-cell antitumor response: chemokine-secreting dendritic cells can prime tumor-reactive T cells extranodally. Cancer Res 61:8794-8802
9. Kirk CJ, Hartigan-O'Connor D, Nickoloff BJ et al (2001) T cell-dependent antitumor immunity mediated by secondary lymphoid tissue chemokine: augmentation of dendritic cell-based immunotherapy. Cancer Res 61:2062-2070
10. Baggiolini M, Dewald B, Moser B (1997) Human chemokines: an update. Annu Rev Immunol 15:675-705
11. Gunn MD, Tangemann K, Tam C et al (1998) A chemokine expressed in lymphoid high endothelial venules promotes the adhesion and chemotaxis of naive T lymphocytes. Proc Natl Acad Sci USA 95:258-263
12. Cyster JG (1999) Chemokines and the homing of dendritic cells to the T cell areas of lymphoid organs. J Exp Med 189:447-450
13. Hromas R, Kim CH, Klemsz M et al (1997) Isolation and characterization of Exodus-2, a novel C-C chemokine with a unique 37-amino acid carboxyl-terminal extension. J Immunol 159:2554-2558
14. Sharma S, Stolina M, Luo J et al (2000) Secondary lymphoid tissue chemokine mediates T cell-dependent antitumor responses in vivo. J Immunol 164:4558-4563
15. Sharma S, Stolina M, Zhu L et al (2001) Secondary lymphoid organ chemokine reduces pulmonary tumor burden in spontaneous murine bronchoalveolar cell carcinoma. Cancer Res 61:6406-6412
16. Perussia B (1991) Lymphokine-activated killer cells, natural killer cells and cytokines. Curr Opin Immunol 3:49-55
17. Boehm U, Klamp T, Groot M et al (1997) Cellular responses to interferon-gamma. Annu Rev Immunol 15:749-795
18. Shankaran V, Ikeda H, Bruce AT et al (2001) IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410:1107-1111
19. Yanagihara K, Seyama T, Watanabe Y (1994) Antitumor potential of interferon-gamma: retroviral expression of mouse interferon-gamma cDNA in two kinds of highly metastatic mouse tumor lines reduces their tumorigenicity. Nat Immun 13:102-112
20. Musiani P, Allione A, Modica A et al (1996) Role of neutrophils and lymphocytes in inhibition of a mouse mammary adenocarcinoma engineered to release IL-2, IL-4, IL-7, IL-10, IFN-alpha, IFN-gamma, and TNF-alpha. Lab Invest 74:146-157
21. Sadanaga N, Nagoshi M, Lederer JA et al (1999) Local secretion of IFN-gamma induces an antitumor response: comparison between T cells plus IL-2 and IFN-gamma transfected tumor cells. J Immunother 22:315-323
22. Ito T, Amakawa R, Inaba M et al (2001) Differential regulation of human blood dendritic cell subsets by IFNs. J Immunol 166:2961-2969
23. Akbar SM, Kajino K, Tanimoto K et al (1999) Unique features of dendritic cells in IFN-gamma transgenic mice: relevance to cancer development and therapeutic implications. Biochem Biophys Res Commun 259:294-299
24. Koski GK, Lyakh LA, Rice NR (2001) Rapid lipopolysaccharide-induced differentiation of CD14(+) monocytes into CD83(+) dendritic cells is modulated under serum-free conditions by exogenously added IFN-gamma and endogenously produced IL-10. Eur J Immunol 31:3773-3781
25. Ohteki T, Fukao T, Suzue K et al (1999) Interleukin 12-dependent interferon gamma production by CD8alpha+ lymphoid dendritic cells. J Exp Med 189:1981-1986
26. Mizuguchi H, Kay MA (1998) Efficient construction of a recombinant adenovirus vector by an improved in vitro ligation method. Hum Gene Ther 9:2577-2583
27. Liu RY, Wu LZ, Huang BJ et al (2005) Adenoviral expression of a truncated S1 subunit of SARS-CoV spike protein results in specific humoral immune responses against SARS-CoV in rats. Virus Res 112:24-31
28. Finney DJ (1964) Statistical method in biological assay, 2nd edn. Hafner Pub. Co., New York
29. Nishimura N, Nishioka Y, Shinohara T et al (2001) Novel centrifugal method for simple and highly efficient adenovirus-mediated green fluorescence protein gene transduction into human monocyte-derived dendritic cells. J Immunol Methods 253:113-124
30. Nishimura N, Nishioka Y, Shinohara T et al (2001) Enhanced efficiency by centrifugal manipulation of adenovirus-mediated interleukin 12 gene transduction into human monocyte-derived dendritic cells. Hum Gene Ther 12:333-346
31. Delemarre FG, Simons PJ, de Heer HJ et al (1999) Signs of immaturity of splenic dendritic cells from the autoimmune prone biobreeding rat: consequences for the in vitro expansion of regulator and effector T cells. J Immunol 162:1795-1801
32. Duperrier K, Eljaafari A, Dezutter-Dambuyant C et al (2000) Distinct subsets of dendritic cells resembling dermal DCs can be generated in vitro from monocytes, in the presence of different serum supplements. J Immunol Methods 238:119-131
33. Terando A, Roessler B, Mule JJ (2004) Chemokine gene modification of human dendritic cell-based tumor vaccines using a recombinant adenoviral vector. Cancer Gene Ther 11:165-173
34. Arthur JF, Butterfield LH, Roth MD et al (1997) A comparison of gene transfer methods in human dendritic cells. Cancer Gene Ther 4:17-25
35. Zhong L, Granelli-Piperno A, Choi Y et al (1999) Recombinant adenovirus is an efficient and non-perturbing genetic vector for human dendritic cells. Eur J Immunol 29:964-972
36. Fasbender A, Zabner J, Chillon M et al (1997) Complexes of adenovirus with polycationic polymers and cationic lipids increase the efficiency of gene transfer in vitro and in vivo. J Biol Chem 272:6479-6489
37. Dietz AB, Vuk-Pavlovic S (1998) High efficiency adenovirus-mediated gene transfer to human dendritic cells. Blood 91:392-398
38. Aiba S, Tagami H (1998) Dendritic cell activation induced by various stimuli, e.g. exposure to microorganisms, their products, cytokines, and simple chemicals as well as adhesion to extracellular matrix. J Dermatol Sci 20:1-13
39. Bayry J, Lacroix-Desmazes S, Kazatchkine MD et al (2005) Modulation of dendritic cell maturation and function by B lymphocytes. J Immunol 175:15-20
40. Pan J, Zhang M, Wang J et al (2004) Interferon-gamma is an autocrine mediator for dendritic cell maturation. Immunol Lett 94:141-151
41. Mosca PJ, Hobeika AC, Clay TM et al (2000) A subset of human monocyte-derived dendritic cells expresses high levels of interleukin-12 in response to combined CD40 ligand and interferon-gamma treatment. Blood 96:3499-3504
42. Riedl K, Baratelli F, Batra RK et al (2003) Overexpression of CCL-21/secondary lymphoid tissue chemokine in human dendritic cells augments chemotactic activities for lymphocytes and antigen presenting cells. Mol Cancer 2:35-47
43. Morelli AE, Larregina AT, Ganster RW et al (2000) Recombinant adenovirus induces maturation of dendritic cells via an NF-kappaB-dependent pathway. J Virol 74:9617-9628
44. Miller G, Lahrs S, Shah AB et al (2003) Optimization of dendritic cell maturation and gene transfer by recombinant adenovirus. Cancer Immunol Immunother 52:347-358
45. Hensley SE, Giles-Davis W, McCoy KC et al (2005) Dendritic cell maturation, but not CD8+ T cell induction, is dependent on type I IFN signaling during vaccination with adenovirus vectors. J Immunol 175:6032-6041
46. Bacon KB, Premack BA, Gardner P et al (1995) Activation of dual T cell signaling pathways by the chemokine RANTES. Science 269:1727-1730
47. Dairaghi DJ, Soo KS, Oldham ER et al (1998) RANTES-induced T cell activation correlates with CD3 expression. J Immunol 160:426-433
48. Appay V, Dunbar PR, Cerundolo V et al (2000) RANTES activates antigen-specific cytotoxic T lymphocytes in a mitogen-like manner through cell surface aggregation. Int Immunol 12:1173-1182
49. Guo Z, Zhang M, Tang H et al (2005) Fas signal links innate and adaptive immunity by promoting dendritic-cell secretion of CC and CXC chemokines. Blood 106:2033-2041
50. Rodolfo M, Colombo MP (1999) Interleukin-12 as an adjuvant for cancer immunotherapy. Methods 19:114-120
51. Glimcher LH, Townsend MJ, Sullivan BM et al (2004) Recent developments in the transcriptional regulation of cytolytic effector cells. Nat Rev Immunol 4:900-911